US 11,806,399 B2
Excipient compounds for biopolymer formulations
David S. Soane, Palm Beach, FL (US); Philip Wuthrich, Watertown, MA (US); Rosa Casado Portilla, Middleton, MA (US); Robert P. Mahoney, Newbury, MA (US); Mark Moody, Concord, MA (US); and Daniel G. Greene, Reading, MA (US)
Assigned to COMERA LIFE SCIENCES, INC., Woburn, MA (US)
Filed by COMERA LIFE SCIENCES, INC., Woburn, MA (US)
Filed on Feb. 12, 2021, as Appl. No. 17/175,162.
Application 17/175,162 is a continuation of application No. 16/659,046, filed on Oct. 21, 2019.
Application 16/659,046 is a continuation of application No. 15/331,197, filed on Oct. 21, 2016, granted, now 10,478,498, issued on Nov. 19, 2019.
Application 15/331,197 is a continuation in part of application No. 14/966,549, filed on Dec. 11, 2015, granted, now 9,605,051, issued on Mar. 28, 2017.
Application 14/966,549 is a continuation of application No. 14/744,847, filed on Jun. 19, 2015, abandoned.
Claims priority of provisional application 62/014,784, filed on Jun. 20, 2014.
Claims priority of provisional application 62/083,623, filed on Nov. 24, 2014.
Claims priority of provisional application 62/136,763, filed on Mar. 23, 2015.
Claims priority of provisional application 62/245,513, filed on Oct. 23, 2015.
Prior Publication US 2021/0162046 A1, Jun. 3, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/24 (2006.01); C07K 16/32 (2006.01); C07K 16/22 (2006.01); A61K 47/22 (2006.01); A61K 47/12 (2006.01); A61K 47/02 (2006.01); A61K 38/17 (2006.01); A61K 47/20 (2006.01); A61K 47/18 (2017.01); A61K 47/42 (2017.01); A61K 47/60 (2017.01); C12N 9/36 (2006.01); C12N 9/96 (2006.01); A61K 38/19 (2006.01); A61K 38/18 (2006.01)
CPC A61K 39/39591 (2013.01) [A61K 38/1793 (2013.01); A61K 38/1816 (2013.01); A61K 38/193 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61K 47/18 (2013.01); A61K 47/20 (2013.01); A61K 47/22 (2013.01); A61K 47/42 (2013.01); A61K 47/60 (2017.08); C07K 16/22 (2013.01); C07K 16/241 (2013.01); C07K 16/32 (2013.01); C12N 9/2462 (2013.01); C12N 9/96 (2013.01); C12Y 302/01017 (2013.01)] 25 Claims
 
1. An injectable liquid pharmaceutical formulation comprising:
a) at least about 10 mg/ml therapeutic antibody;
b) a viscosity reducing amount of caffeine, wherein the viscosity reducing amount of caffeine is 2% or less by weight of the injectable liquid pharmaceutical formulation; and
c) a viscosity reducing amount of an aromatic acid,
wherein viscosity of the injectable liquid pharmaceutical formulation is less than about 100 cP.